Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1)

Regulatory Toxicology and Pharmacology

Volumn 51, Issue 3 SUPPL., 2008, Pages

  Hays, Sean M ^a   Aylward, Lesa L ^a  

^a LLP   (United States)

Author keywords

Acrylamide; BEs; Biomonitoring Equivalents; Blood; Risk assessment; Screening; Urine

Indexed keywords

ACRYLAMIDE; BIOLOGICAL MARKER; CYSTEINE; HEMOGLOBIN; VALINE;

ALCOHOL CONSUMPTION; ARTICLE; BIOLOGICAL MONITORING; BLOOD LEVEL; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); DATA BASE; DRUG USE; ENVIRONMENTAL PROTECTION; GENDER; GENETIC POLYMORPHISM; GROUPS BY AGE; HEALTH CARE ORGANIZATION; HEALTH HAZARD; HUMAN; KINETICS; NERVE INJURY; NEUROTOXICITY; NONHUMAN; POPULATION EXPOSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; SMOKING; STEADY STATE; URINALYSIS; URINARY EXCRETION; URINE LEVEL; WORLD HEALTH ORGANIZATION;

ACRYLAMIDE; ANIMALS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; EPOXY COMPOUNDS; GLUTATHIONE; GUIDELINES AS TOPIC; HEMOGLOBINS; HUMANS; MODELS, BIOLOGICAL; RISK ASSESSMENT; RISK MANAGEMENT; VALINE;

EID: 47549095485     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2008.05.010     Document Type: Article

References (38)

1. Barr D.B., Wilder L.C., Caudill S.P., Gonzalez A.J., Needham L.L., and Pirkle J.L. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ. Health Perspect. 113 (2005) 192-200
2. Bergmark E., Calleman C.J., and Costa L.G. Formation of hemoglobin adducts of acrylamide and its epoxide metabolite glycidamide in the rat. Toxicol. Appl. Pharmacol. 111 (1991) 352-363
3. Bjellaas T., Janák P.T.K., Lundanes H.E., Kronberg M.L., and Becher L.H.G. Determination and quantification of urinary metabolites after dietary exposure to acrylamide. Xenobiotica 35 (2005) 1003-1018
4. Bjellaas T., Olesen K.P.T., Frandsen H., Haugen M., Stolen L.H., Paulsen J.E., Alexander E.J., Lundanes L.E., and Becher G. Comparison of estimated dietary intake of acrylamide with haemoglobin adducts of acrylamide and glycidamide. Toxicol. Sci. 98 (2007) 110-117
5. Boettcher M.I., and Angerer J. Determination of the major mercapturic acids of acrylamide and glycidamide in human urine by LC-ESI-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 824 (2005) 283-294
6. Boettcher M.I., Schettgen H.M.T., Kutting B., Pischetsrieder M., and Angerer J. Mercapturic acids of acrylamide and glycidamide as biomarkers of the internal exposure to acrylamide in the general population. Mutat. Res. 580 (2005) 167-176
7. Boettcher M.I., Bolt T.H.M., Drexler B.H., and Angerer J. Excretion of mercapturic acids of acrylamide and glycidamide in human urine after single oral administration of deuterium-labelled acrylamide. Arch. Toxicol. 80 (2006) 55-61
8. Burek J.D., Albee R.R., Beyer J.E., Bell T.J., Carreon R.M., Morden D.C., Wade C.E., Hermann E.A., and Gorzinski S.J. Subchronic toxicity of acrylamide administered to rats in the drinking water followed by up to 144 days of recovery. J. Environ. Pathol. Toxicol. 4 (1980) 157-182
9. Doerge D.R., Young J.F., McDaniel L.P., Twaddle N.C., and Churchwell M.I. Toxicokinetics of acrylamide and glycidamide in Fischer 344 rats. Toxicol. Appl. Pharmacol. 208 (2005) 199-209
10. Doerge R.D., Gamboa de Costa G., McDaniel L.P., Churchwell M.I., Twaddle N.C., and Beland F.A. DNA adducts derived from administration of acrylamide and glycidamide to mice and rats. Mutat. Res. 580 (2005) 131-141
11. Dybing E., and Sanner T. Risk assessment of acrylamide in foods. Toxicol. Sci. 75 (2003) 7-15
12. Dybing E., Farmer P.B., Andersen M., Fennell T.R., Lalljie S.P., Muller D.J., Olin S., Petersen B.J., Schlatter J., Scholz G., Scimeca J.A., Slimani N., Tornqvist M., Tuijtelaars S., and Verger P. Human exposure and internal dose assessments of acrylamide in food. Food Chem. Toxicol. 43 (2005) 365-410
13. European Chemicals Bureau (ECB), 2002. European risk assessment report: acrylamide. Accessed 11/30/07 at http://ecb.jrc.it/DOCUMENTS/Existing-Chemicals/RISK_ASSESSMENT/REPORT/acrylamidereport011.pdf.
14. Fennell T.R., Sumner S.C., Snyder R.W., Burgess J., Spicer R., Bridson W.E., and Friedman M.A. Metabolism and hemoglobin adduct formation of acrylamide in humans. Toxicol. Sci. 85 (2005) 447-459
15. Fennell T.R., Sumner S.C., Snyder R.W., Burgess J., and Friedman M.A. Kinetics of elimination of urinary metabolites of acrylamide in humans. Toxicol. Sci. 93 (2006) 256-267
16. Fuhr U., Boettcher M.I., Kinzig-Schippers M., Weyer A., Jetter A., Lazar A., Taubert D., Tomalik-Scharte D., Pournara P., Jakob V., Harlfinger S., Klaassen T., Berkessel A., Angerer J., Sorgel F., and Schomig E. Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 266-271
17. Garde A.H., Hansen A.M., Kristiansen J., and Knudsen L.E. Comparison of uncertainties related to standardization of urine samples with volume and creatinine concentration. Ann. Occup. Hyg. 48 (2004) 171-179
18. Ghanayem B.I., McDaniel L.P., Churchwell M.I., Twaddle N.C., Snyder R., Fennell T.R., and Doerge D.R. Role of CYP2E1 in the epoxidation of acrylamide to glycidamide and formation of DNA and hemoglobin adducts. Toxicol. Sci. 88 (2005) 311-318
19. Hagmar L., Wirfalt E., Paulsson B., and Tornqvist M. Differences in hemoglobin adduct levels of acrylamide in the general population with respect to dietary intake, smoking habits and gender. Mutat. Res. 580 (2005) 157-165
20. Hays S.M., Becker R.A., Leung H.W., Aylward L.L., and Pyatt D.W. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regul. Toxicol. Pharmacol. 47 (2007) 96-109
21. Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk C., DiZio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.-M., Viau C., and Yager J.W. Guidelines for the derivation of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Reg. Toxicol. Pharmacol. 51 (2008) S4-S15
22. Johnson K.A., Gorzinski S.J., Bodner K.M., Campbell R.A., Wolf C.H., Friedman M.A., and Mast R.W. Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol. Appl. Pharmacol. 85 (1986) 154-168
23. Kirman C.R., Gargas M.L., Deskin R., Tonner-Navarro L., and Andersen M.E. A physiologically based pharmacokinetic model for acrylamide and its metabolite, glycidamide, in the rat. J. Toxicol. Environ. Health A 66 (2003) 253-274
24. Kissel J.C., Curl C.L., Kedan G., Lu C., Griffith W., Barr D.B., Needham L.L., and Fenske R.A. Comparison of organophosphorus pesticide metabolite levels in single and multiple daily urine samples collected from preschool children in Washington State. J. Expo. Anal. Environ. Epidemiol. 15 (2005) 164-171
25. LaKind J.S., Aylward L.L., Brunk C., DiZio S., Dourson M., Goldstein D.A., Kilpatrick M.E., Krewski D., Bartels M., Barton H.A., Boogaard P.J., Lipscomb J., Krishnan K., Nordberg M., Okino M., Tan Y.-M., Viau C., Yager J.W., and Hays S.M. Guidelines for the communication of biomonitoring equivalents: report from the biomonitoring equivalents expert workshop. Reg. Toxicol. Pharmacol. 51 Suppl. 1 (2008) S16-S26
26. Mage D.T., Allen R.H., Gondy G., Smith W., Barr D.B., and Needham L.L. Estimating pesticide dose from urinary pesticide concentration data by creatinine correction in the Third National Health and Nutrition Examination Survey (NHANES-III). J. Expo. Anal. Environ. Epidemiol. 14 (2004) 457-465
27. Nong A., McCarver D.G., Hines R.N., and Krishnan K. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol. 214 (2006) 78-87
28. O'Rourke M.K., Lizardi P.S., Rogan S.P., Freeman N.C., Aguirre A., and Saint C.G. Pesticide exposure and creatinine variation among young children. J. Expo. Anal. Environ. Epidemiol. 10 (2000) 672-681
29. Osterman-Golkar S., Ehrenberg L., Segerbäck D., and Hällstrom I. Evaluation of genetic risks of alkylating agents. II. Hemoglobin as a dose monitor. Mutat. Res. 34 (1976) 1-10
30. Paulsson B., Warholm M., Rannug A., and Tornqvist M. In vitro studies of the influence of certain enzymes on the detoxification of acrylamide and glycidamide in blood. Adv. Exp. Med. Biol. 561 (2005) 127-133
31. Perucca J., Bouby N., Valeix P., and Bankir L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R700-R705
32. Remer T., Neubert N.A., and Maser-Gluth U.C. Anthropometry-based reference values for 24-h urinary creatinine excretion during growth and their use in endocrine and nutritional research. Am. J. Clin. Nutr. 75 (2002) 561-569
33. Remer T., Fonteyn N., Alexy U., and Berkemeyer C.S. Longitudinal examination of 24-h urinary iodine excretion in schoolchildren as a sensitive, hydration status-independent research tool for studying iodine status. Am. J. Clin. Nutr. 83 (2006) 639-646
34. Shipp A., Lawrence G., Gentry R., McDonald T., Bartow H., Bounds J., Macdonald N., Clewell H., Allen B., and Van Landingham C. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects. Crit. Rev. Toxicol. 36 (2006) 481-608
35. Tareke E., Twaddle N.C., McDaniel L.P., Churchwell M.I., Young J.F., and Doerge D.R. Relationships between biomarkers of exposure and toxicokinetics in Fischer 344 rats and B6C3F1 mice administered single doses of acrylamide and glycidamide and multiple doses of acrylamide. Toxicol. Appl. Pharmacol. 217 (2006) 63-75
36. United States Environmental Protection Agency (USEPA), 2007a. Acrylamide. Integrated Risk Information System (IRIS) record accessed 11/30/07 at http://toxnet.nlm.nih.gov/.
37. United States Environmental Protection Agency (USEPA), 2007b. Toxicological review of acrylamide (CAS No. 79-06-1). In support of summary information on the Integrated Risk Information System (IRIS) http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=187729.
38. Young J.F., Luecke R.H., and Doerge D.R. Physiologically based pharmacokinetic/pharmacodynamic model for acrylamide and its metabolites in mice, rats, and humans. Chem. Res. Toxicol. 20 (2007) 388-399